Indivior PLC, a revenue-generating company in the opioid dependence market, is trading near 52-week lows despite strong financials and solid prospects. The company faces competition, especially from ...
With the significant treatment gap, Indivior is well positioned for growth as more patients receive treatment for Opioid Use Disorder. Sublocade, the first FDA-approved buprenorphine LAI for OUD, has ...
Expects slower near term growth for Sublocade Sublocade sales impacted by rapid adoption of Camurus' Brixadi Shares fell as much as 21.5%, lowest since 2021 Oct 10 (Reuters) - British drugmaker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results